IPP Bureau
Tillotts Pharma and TVM Capital form Mage Biologics to develop oral antibody therapy for ulcerative colitis
By IPP Bureau - July 21, 2023
Mage Biologics to develop a monoclonal antibody targeting ulcerative colitis
Kintor Pharma completes first patient enrollment in long-term safety phase III trial of KX-826
By IPP Bureau - July 21, 2023
The Long-term Safety Trial was approved to be conducted by China National Medical Products Administration (NMPA) on 18 April 2023
Riparian Pharmaceuticals inks license and research agreement with Pfizer for cardiovascular programs
By IPP Bureau - July 21, 2023
Pfizer will make upfront and milestone payments, as well as pay royalties on sales of resulting therapeutics
Merck’s Phase 3 Keynote- A18 trial met PFS in patients with advanced cervical cancer
By IPP Bureau - July 21, 2023
KEYTRUDA plus concurrent chemoradiotherapy demonstrated statistically significant and clinically meaningful improvement in PFS versus concurrent chemoradiotherapy alone in these patients
M&A activity of pharma CMOs will continue despite challenging borrowing environment, says GlobalData
By IPP Bureau - July 20, 2023
CMOs showed an increasing reluctance to take on debt in 2022
Wockhardt Hospitals, Mira Road launches training program for family physician
By IPP Bureau - July 20, 2023
To equip them with the latest knowledge and skills to handle patients coming to them in a better way
GE HealthCare expands partnership with TCS to transform IT operating model
By IPP Bureau - July 20, 2023
This transformation will enable GE HealthCare to build a strong foundation for business growth
Briefs: Shivalik Rasayan and Dr. Reddy's Laboratories
By IPP Bureau - July 20, 2023
Shivalik Rasayan Limited has issued LOA to Medicamen Biotech to use its DMF grade Bortezomib API for formulation of Bortezomib injection 3.5mg/ vial
Sandoz plans to build a Biosimilar Technical Development Center in Slovenia
By IPP Bureau - July 20, 2023
Planned investment of approximately USD 90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026
Healthcare Triangle awarded contract expansion with Fortune 500 biopharmaceutical customer
By IPP Bureau - July 20, 2023
The agreement extends the customer's suite of cloud DevOps, data engineering, and data platform management solutions
Novartis acquires DTx Pharma to develop siRNA therapies
By IPP Bureau - July 19, 2023
Deal includes DTx-1252, a potential therapy for the neuromuscular disorder Charcot-Marie-Tooth disease type 1A (CMT1A), and two additional preclinical programs for other neuroscience indications
SEBI approves Piramal Pharma’s Rs 1,050-crore rights issue
By IPP Bureau - July 19, 2023
Piramal Pharma plans to offer fully paid-up equity shares through a rights issue to its existing eligible shareholders
PrecisionLife identifies first detailed genetic risk factors for long COVID
By IPP Bureau - July 19, 2023
Long COVID is a debilitating chronic condition that has affected over 100 million people globally
Helping Hand Foundation launches screening for glaucoma in Hyderabad
By IPP Bureau - July 19, 2023
First of its kind screening for Glaucoma at grass root level over 10k screened already
Strand Life Sciences expands sequencing facility
By IPP Bureau - July 19, 2023
The newly launched Genomic Health Insights (GHI) program to make sequencing accessible to all
